Lifecore Biomedical
LFCR
100 hedge funds and large institutions have $199M invested in Lifecore Biomedical in 2025 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 27 increasing their positions, 30 reducing their positions, and 6 closing their positions.
233% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 6
16% more funds holding
Funds holding: 86 → 100 (+14)
1.57% less ownership
Funds ownership: 66.57% → 65.01% (-1.6%)
10% less capital invested
Capital invested by funds: $221M → $199M (-$21.4M)
10% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 30
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
98% less call options, than puts
Call options by funds: $5K | Put options by funds: $261K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
+$907K |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$596K |
| 3 |
Millennium Management
New York
|
+$510K |
| 4 |
Jane Street
New York
|
+$501K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$283K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$2.77M |
| 2 |
2L
22NW LP
Seattle,
Washington
|
-$1.99M |
| 3 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
-$746K |
| 4 |
BlackRock
New York
|
-$259K |
| 5 |
Morgan Stanley
New York
|
-$228K |
LFCR Hedge Fund Activity: Q3 2025 in Review
100 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q3 2025, worth a combined $199M — down 9.7% from $221M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new LFCR positions and 6 closed out — a net gain of 14 holders — while 27 added to existing stakes and 30 trimmed.
The largest buyer was Squarepoint, adding an estimated $907K. The largest seller was Invesco, cutting an estimated $2.77M.
- 100 institutional investors held Lifecore Biomedical (LFCR) as of Q3 2025, up from 86 in Q2 2025.
- Funds reported $199M of Lifecore Biomedical stock for Q3 2025, down 9.7% quarter-over-quarter.
- 20 funds opened new Lifecore Biomedical positions in Q3 2025 and 6 closed out, a net change of +14 holders.
- The largest Lifecore Biomedical buyer in Q3 2025 was Squarepoint, an estimated $907K added.
- The largest Lifecore Biomedical seller in Q3 2025 was Invesco, an estimated $2.77M sold.
Based on aggregated 13F filings for Q3 2025.